Extract from the Register of European Patents

EP Citations: EP3102608

Cited inInternational search
Type:Patent literature
Publication No.:WO2013006706  [XI]
 (BIOASIS TECHNOLOGIES INC et al.) [X] 1,15,17,20,24,28,42,45,46 * sequence 1 * * claims 1-62 * * examples 1-5 * * pages 36-39 * * pages 53-56 *[I] 2-14,16,18,19,21-23,25-27,29-41,43,44,47-64
Type:Patent literature
Publication No.:WO2013022738  [XI]
 (BIOASIS TECHNOLOGIES INC et al.) [X] 1,17,20,24,28,42,45,46 * sequences 12,1 * * claims 1-48 *[I] 2-16,18,19,21-23,25-27,29-41,43,44,47-64
Type:Patent literature
Publication No.:WO2014160438  [XP]
 (BIOASIS TECHNOLOGIES INC et al.) [XP] 1,17,20,24,28,42,45,46 * sequence 13 * * claims 1-59 * * examples 3-4 *
Type:Non-patent literature
Publication information:[X]   REINHARD GABATHULER ET AL: "BT2111, a new anticancer agent composed of trastuzumab and transcend a vector for brain delivery for the treatment of metastatic Her2+ breast cancer", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 12, 1 November 2013 (2013-11-01), XP009183826, ISSN: 1535-7163 [X] 1,17,20,24,28,42,45,46 * the whole document *
DOI: http://dx.doi.org/10.1158/1535-7163.TARG-13-A247
Type:Non-patent literature
Publication information:[A]   BYRON DELABARRE ET AL: "Central Pore Residues Mediate the p97/VCP Activity RTequired for ERAD", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 22, no. 4, 19 May 2006 (2006-05-19), pages 451 - 462, XP002683495, ISSN: 1097-2765, DOI: 10.1016/J.MOLCEL.2006.03.036 [A] 1-64 * abstract *
DOI: http://dx.doi.org/10.1016/J.MOLCEL.2006.03.036
Type:Non-patent literature
Publication information:[A]   DELARA KARKAN ET AL: "A Unique Carrier for Delivery of Therapeutic Compounds beyond the Blood-Brain Barrier", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 3, no. 6, 1 June 2008 (2008-06-01), pages E2469.1 - E2469.14, XP002685120, ISSN: 1932-6203, [retrieved on 20080625], DOI: 10.1371/JOURNAL.PONE.0002469 [A] 1-64 * abstract *
DOI: http://dx.doi.org/10.1371/JOURNAL.PONE.0002469